Sandoz loses challenge to patent on Amgen’s $5.2B autoimmune drug, may appeal to Supreme Court

A large biotech company will maintain patent protection on one of its key products for the next several years following a federal court’s ruling that a biosimilar challenger infringed on its patents.

https://medcitynews.com/2020/07/sandoz-loses-challenge-to-patent-on-amgens-5-2b-autoimmune-drug-may-appeal-to-supreme-court/?rf=1